Conjugate Vaccine Market to receive overwhelming hike in Revenues by 2025

Conjugate vaccines are vaccines for infectious diseases. There are special polysaccharide coatings on some bacteria and viruses that help them to escape the immune system. An immature immune system can recognize these bacteria with the help of the conjugate vaccines, as these vaccines link the special polysaccharide coatings to an organism by producing immunity and response. The examples of conjugate vaccines are meningococcal vaccine to prevent meningitis, haemophilus influenzae type B (Hib) vaccine, and pneumococcal vaccine.

Report Overview @ https://www.transparencymarketresearch.com/conjugate-vaccine-market.html

Increased revenue from the sale of meningococcal vaccines and pneumococcal vaccines are driving the global conjugate vaccine market due to increasing advancements in the research and development. Increasing prevalence of infectious diseases and rising awareness toward prevention of these disease is anticipated to boost the global conjugate vaccine market during the forecast period. However, long time interval between the introduction of new conjugate vaccines in low-income countries and high-income countries is likely to restrain the global conjugate vaccine market. According to the U.S. National Library of Medicine, National Institutes of Health, high mortality and morbidity are caused due to vaccine-preventable diseases. In 2010, 87% of the population of high-income countries had pneumococcal conjugate vaccines in their immunization schedules, whereas only 2% had pneumococcal conjugate vaccines in their immunization schedules among the total population of low-income countries.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30452

The global conjugate vaccine market can be classified on the basis of product type, disease indication, pathogen type, patient type, and region. In terms of product type, the global conjugate vaccine market can be segmented into multivalent conjugate vaccines and monovalent conjugate vaccines. The monovalent conjugate vaccines segment held the major share of the market in 2016 due to the high awareness and high quality vaccines provided by key players. However, the multivalent conjugate vaccines segment is anticipated to expand in the near future due to the improvements in technology and government initiatives.

In terms of disease indication, the global conjugate vaccine market can be segmented into meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and others. The diphtheria tetanus pertussis segment of the global conjugate vaccine market expanded in 2016 due to its high prevalence and highly contagious nature of the respiratory tract infection. The pneumococcal segment of the global conjugate vaccine market is anticipated to expand during the forecast period, as it is the most attractive segment in the market, in terms of technology. In terms of pathogen type, the global conjugate vaccine market can be segmented into combination (viral and bacterial) conjugate vaccine, viral conjugate vaccine, and bacterial conjugate vaccine. In terms of patient type, the market can be segmented into adults conjugate vaccine and pediatrics conjugate vaccine. The pediatrics conjugate vaccine segment held a major share of the global market in 2016 due to the high prevalence of infectious diseases among children.

Geographically, the global conjugate vaccine market can be segmented into Asia Pacific, Europe, North America, Latin America, and Middle East & Africa. In terms of technology, North America is projected to be the most attractive market for conjugate vaccine during the forecast period, due to rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. The market in Asia Pacific is anticipated to expand during the forecast period due to increasing immunization initiatives by organizations such as GAVI and World Health Organization in emerging economies such as India and China. Increasing focus of major players on the market in India and governmental initiatives for infectious diseases are likely to fuel the demand for the conjugate vaccines in the region.

Key players operating in the global conjugate vaccine market include Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Pfizer, Inc., Novartis AG, Neuron Biotech, Merck & Co., Inc., GlaxoSmithKline plc, CSL Behring, Biological E, and Bharat Biotech.

Pre Book full report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=30632<ype=S

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/

This release was published on openPR.